We will consider any manuscript that addresses cardiovascular disease in humans. This runs the gamut from first in human investigations to multicenter randomized clinical trials to population-based clinical, genetic, or biomarker epidemiological investigations. Given that JAMA also is interested in translating science into practice, we also encourage submission of studies that examine health care quality, safety, and efficiency; implementation evaluations; and other relevant health policy issues. With the timing of this theme issue, we are especially interested in late-breaking research, particularly late-breaking randomized clinical trials that will be presented at the American Heart Association meeting. We encourage authors who are involved with such studies to contact us as early as possible so that we can discuss our interest in the trial and coordinate timing for submission of the manuscript with the goal of simultaneous publication at the time of the scientific presentation. We also are interested in receiving scholarly, thought-provoking Viewpoints on important and timely clinical and policy topics in cardiovascular medicine.